Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the MAMMOTH and STORM (NCT02336815) studies evaluating selinexor in refractory myeloma. The efficacy of selinexor in combination with low-dose dexamethasone was demonstrated in the pivotal Phase 2 STORM study (NCT02336815). The results of the MAMMOTH study have been used as a benchmark to refer to. Analysis of the MAMMOTH population and the STORM population saw an improvement in overall survival with selinexor in refractory patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Research support : Amgen, Janssen Honorarium: BMS, Janssen, Amgen, Genentech, Astra Zeneca